Kevin Balthaser - 01 Mar 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Financial Officer
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Mar 2026
Net transactions value: -$1,943
Form type: 4
Filing time: 03 Mar 2026, 16:10:13 UTC
Previous filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Balthaser Kevin	Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE	/s/ Matthew Rothman, Attorney-in-Fact	03 Mar 2026	0001957554

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+2,375	+1.3%		188,130	01 Mar 2026	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$1,943	-677	-0.36%	$2.87	187,453	01 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-2,375	-100%	$0.000000	0	01 Mar 2026	Common Stock	2,375		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.